Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipelineGlobeNewsWire • 10/26/25
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reportsCNBC • 10/26/25
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reportsReuters • 10/26/25
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseasesGlobeNewsWire • 10/25/25
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 10/23/25
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)GlobeNewsWire • 10/22/25
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offerGlobeNewsWire • 10/22/25
Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancerReuters • 10/19/25
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancerGlobeNewsWire • 10/19/25
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient populationGlobeNewsWire • 10/17/25
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CMLGlobeNewsWire • 10/17/25
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)GlobeNewsWire • 10/16/25
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump DealZacks Investment Research • 10/08/25